Mankind Pharma
Mankind Pharma is a leading Indian pharmaceutical company that develops, manufactures, and markets a wide range of pharmaceutical products. It is the fourth-largest pharmaceutical company in India in terms of domestic sales and the second-largest in terms of sales volume.
The company focuses on the domestic market, which contributed 97.6% of its total revenue in FY 2022. It has created 36 brands that have each achieved over INR 50 crore in domestic sales in FY 2022. Mankind Pharma is present in several therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, anti-diabetic, neuro/CNS, vitamins/minerals/nutrients, and respiratory.
The company has 23 manufacturing facilities across India and a total installed capacity of 40.77 billion units. It has a team of over 600 scientists and a dedicated in-house R&D center.
Mankind Pharma IPO Details
| Signature Global IPO Details | ||
|---|---|---|
|
Mankind Pharma IPO Dates |
25 – 27 April 2023 |
|
|
Mankind Pharma IPO Price |
INR 1,026 – 1,080 per share |
|
|
Fresh issue |
Nil |
|
|
Offer For Sale |
4,00,58,844 shares (INR 4,110.04 – 4,326.36 crore) |
|
|
Total IPO Size |
INR 4,326.36 crore |
|
|
Minimum bid (size) |
13 shares (INR 14,040) |
|
|
Face Value |
INR 1 per share |
|
|
Retail Allocation |
35% |
|
|
Listing On |
BSE, NSE |
|
Mankind Pharma Financial Performance
| Signature Global Financial Performance | ||||
|---|---|---|---|---|
|
|
FY2020 |
FY2021 |
FY2022 |
9M FY 2023 |
|
Revenue |
5,865.2 |
6,214.4 |
7,781.6 |
6,696.8 |
|
Expenses |
4,549.5 |
4,705.5 |
6,017.4 |
5,493.5 |
|
Net income |
1,056.2 |
1,293.0 |
1,453.0 |
1,010.2 |
|
Margin (%) |
18.0 |
20.8 |
18.7 |
15.1 |
Figures in INR Crore unless specified otherwise